Related Experiment Video
Updated: Jun 8, 2026
05:51
Characterization of a Novel Human Organotypic Retinal Culture Technique
Published on: June 9, 2021
Interleukin-4 gene polymorphisms in type 2 diabetic patients with nephropathy
1Department of Microbiology, Hematology, and Immunology, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. kazemim@modares.ac.ir.
Iranian Journal of Kidney Diseases
|September 21, 2010
Summary
Genetic variations in the interleukin-4 (IL-4) gene
Area of Science:
- Genetics
- Immunology
- Endocrinology
Background:
- Diabetes mellitus and its complications are influenced by environmental and genetic factors.
- Cytokines are implicated in the pathogenesis of nephropathy.
- Interleukin-4 (IL-4) gene expression is regulated by polymorphisms in its -590 region.
Purpose of the Study:
- To investigate polymorphisms in the -590 region of the IL-4 gene.
- To assess the association of these polymorphisms with diabetic nephropathy in type 2 diabetes mellitus patients.
Main Methods:
- Peripheral blood samples were collected from 100 type 2 diabetic patients with nephropathy and 150 healthy controls.
- DNA was extracted from blood samples.
- Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to analyze IL-4 gene polymorphisms at the -590 region.
Main Results:
- Significant differences in C/C, T/C, and T/T genotypes and C and T alleles of the IL-4 -590 region were observed.
- These differences were noted between nephropathic patients and healthy controls.
Conclusions:
- Functional gene polymorphisms of IL-4 are associated with the pathogenesis of diabetic nephropathy.
- IL-4 gene variations may play a significant role in the development of diabetic nephropathy in type 2 diabetes mellitus.
Related Concept Videos
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:28Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.